ClinicalTrials.Veeva

Menu

Electronic PHES vs Paper-based PHES for Hepatic Encephalopathy

N

Nanjing Medical University

Status

Not yet enrolling

Conditions

Minimal Hepatic Encephalopathy
Hepatic Encephalopathy
Liver Cirrhosis

Treatments

Diagnostic Test: Paper-based Psychometric Hepatic Encephalopathy Score (PHES)
Diagnostic Test: Electronic Psychometric Hepatic Encephalopathy Score (PHES)

Study type

Interventional

Funder types

Other

Identifiers

NCT07852416
2026-SR-580

Details and patient eligibility

About

This is a prospective, multicenter, randomized crossover diagnostic accuracy study. A total of 80 patients with liver cirrhosis will be enrolled and randomly assigned to two sequence groups at a 1:1 ratio. Participants in Sequence A will complete the paper-based Psychometric Hepatic Encephalopathy Score (PHES) on Day 1 and the electronic PHES on Day 2; participants in Sequence B will receive the tests in reverse order. All tests will be performed at the same time of day with a 1-day washout interval to minimize carryover effect. The primary objective is to verify the equivalence of total scores between electronic and paper-based PHES. Secondary objectives include evaluating the consistency of MHE classification and individual subtest scores, and analyzing the effects of test sequence and time period on results. This study aims to provide evidence for clinical promotion of the electronic PHES tool.

Full description

This is a randomized crossover diagnostic accuracy study. Each eligible participant will receive both the electronic PHES and paper-based PHES tests in a randomly assigned sequence, with a 1-day washout interval between the two tests.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Aged 18 to 75 years
  2. Confirmed diagnosis of liver cirrhosis based on clinical, laboratory, imaging, or liver biopsy evidence
  3. Intact cognitive function, no overt hepatic encephalopathy (West-Haven grade ≥ II), and able to cooperate with neuropsychological tests
  4. Voluntarily signed written informed consent with good compliance and full understanding of the study

Exclusion criteria

  1. Concomitant uncontrolled neuropsychiatric diseases affecting cognitive function (e.g., Alzheimer's disease, Parkinson's disease, post-stroke sequelae, severe depression/anxiety, schizophrenia)
  2. Use of hypnotics, sedatives, or psychotropic drugs within the past 1 month
  3. Severe alcohol dependence or substance abuse, unable to maintain abstinence
  4. Current use of lactulose at screening

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

80 participants in 2 patient groups

Group A (Paper-then-Electronic Sequence)
Other group
Description:
Participants receive paper-based PHES test on Day 1, and receive electronic PHES test on Day 2 with a 1-day washout interval between two tests.
Treatment:
Diagnostic Test: Electronic Psychometric Hepatic Encephalopathy Score (PHES)
Diagnostic Test: Paper-based Psychometric Hepatic Encephalopathy Score (PHES)
Group B (Electronic-then-Paper Sequence)
Other group
Description:
Participants receive electronic PHES test on Day 1, and receive paper-based PHES test on Day 2 with a 1-day washout interval between two tests.
Treatment:
Diagnostic Test: Electronic Psychometric Hepatic Encephalopathy Score (PHES)
Diagnostic Test: Paper-based Psychometric Hepatic Encephalopathy Score (PHES)

Trial documents
1

Trial contacts and locations

2

Loading...

Central trial contact

Longfeng Jiang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems